Bristol-Myers to invest in Compugen, collaborate in clinical trials

Bristol-Myers to invest in Compugen, collaborate in clinical trials

Bristol-Myers to invest in Compugen, collaborate in clinical trialsBristol-Myers to invest in Compugen, collaborate in clinical trials

TEL AVIV (Reuters) – Bristol-Myers Squibb Co and Israel’s Compugen said on Thursday they will collaborate in clinical trials for patients with advanced solid tumors.

The trials will evaluate the safety and tolerability of Compugen’s COM701, an investigational antibody, in combination with Bristol-Myers Squibb’s immune checkpoint inhibitor Opdivo.

In conjunction with the collaboration, Bristol-Myers Squibb will invest $12 million in Compugen, purchasing 2,424,243 shares – equal to a 4.1 percent stake – at $4.95 each. The investment represents a 33 percent premium over the average closing price on the last 20 trading days and is expected to close on or about Oct. 12.

Compugen will sponsor an ongoing two-part early stage trial, which includes evaluating the combination of COM701 and Opdivo in four tumor types, including non-small cell lung, ovarian, breast and endometrial cancer. The collaboration is also designed to address potential future combinations.

Opdivo, approved in over 60 countries, is designed to harness the body’s immune system to help restore anti-tumor immune response.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.


Source : Reuters Link

Related Post